Futura Medical Regulatory News (FUM)

9 Apr 2008 07:00

Futura Medical PLC09 April 2008 For Immediate Release 9 April 2008 Futura Medical Plc ("Futura" or "the Company") Update on topical pain relief project Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for consumer healthcare, can provide the following update on itstopical pain relief project, TPR100, using Futura's proprietary trans-dermaldelivery technology, DermaSys(R). Completion of clinical studies to evaluate drug delivery using Futura's Dermasys(R) technology has been extended to complete formulation optimisation.Commercial negotiations are continuing on a non-exclusive basis. We will provide further updates to shareholders at the earliest opportunity. For further information: Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: www.futuramedical.co.ukjames.barder@futuramedical.co.uk Canaccord AdamsRyan Gaffney / Adria Da Breo Tel: +44 (0) 20 7050 6500 Media enquiries:Buchanan CommunicationsMark Court / Rebecca Skye Dietrich Tel: +44 (0) 020 7466 5000 Notes to Editors Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange